Improvement in MRI outcomes across subgroups with alemtuzumab versus interferon beta-1a in treatment-naive relapsing-remitting multiple sclerosis

被引：0
|
作者：
Montalban, X. [1 ]
Arnold, D. L. [2 ,3 ]
Fisher, E. [4 ]
Margolin, D. H. [5 ]
Palmer, J. [5 ]
机构：
[1] Vall dHebron Univ Hosp & Res Inst, Edifici Cemcat, Barcelona, Spain
[2] NeuroRx Res, Montreal, PQ, Canada
[3] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[4] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA
[5] Genzyme, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P039
引用
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [1] Alemtuzumab demonstrates improvement in MRI outcomes across baseline subgroups versus subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy
    Barkhof, F.
    Fisher, E.
    Palmer, J.
    Margolin, D. H.
    Arnold, D. L.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S90 - S91
  • [2] Alemtuzumab demonstrates improvement in MRI outcomes across baseline subgroups versus subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy
    Barkhof, F.
    Fisher, E.
    Palmer, J.
    Margolin, D. H.
    Arnold, D. L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 126 - 127
  • [3] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    [J]. HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
  • [4] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [5] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
    Vazquez Gomez, Lazaro Aurelio
    Hidalgo Mesa, Carlos
    Broche Perez, Yunier
    Valdes Morales, Yanet
    [J]. MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
  • [6] Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
    Munschauer, FE
    Stuart, WH
    [J]. CLINICAL THERAPEUTICS, 1997, 19 (05) : 868 - 882
  • [7] Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
    Coles, Alasdair J.
    Fox, Edward
    Vladic, Anton
    Gazda, Suzanne K.
    Brinar, Vesna
    Selmaj, Krzysztof W.
    Doan-Do Bass, Ann
    Wynn, Daniel R.
    Margolin, David H.
    Lake, Stephen L.
    Moran, Susan
    Palmer, Jeffrey
    Smith, M. Shelton
    Compston, D. Alastair S.
    [J]. LANCET NEUROLOGY, 2011, 10 (04): : 338 - 348
  • [8] Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
    Liu, Ying
    Vollmer, Timothy
    Havrdova, Eva
    Riester, Katherine
    Lee, Andrew
    Phillips, Glenn
    Wang, Ping
    Sabatella, Guido
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 : 18 - 24
  • [9] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS SUBCUTANEOUS INTERFERON BETA-1A FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Wandstrat, T.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [10] Interferon beta-1a in relapsing-remitting multiple sclerosis: A meta-analysis
    Blumhardt, LD
    [J]. NEUROLOGY, 1999, 52 (06) : A498 - A498
12345